Treatment of Glucocorticoid-Induced Osteoporosis with Alfacalcidol/Calcium Versus Vitamin D/Calcium

Ringe, J. D.; Cöster, A.; Meng, Tong; Schacht, E.; Umbach, Roland

doi:10.1007/s002239900708

Cited by 65 publications

(33 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the appendicular skeleton, treatment with active vitamin D had less effect than on the axial skeleton, which, in keeping with the findings of others (21), may be related to fact that trabecular bone (predominantly present in lumbar spine) is more active and responds faster than cortical bone (mainly present in distal radius). Our results confirmed the significant positive effect of active vitamin D on bone loss reported in short-term studies of nontransplant steroid-treated patients (19), nonrenal transplant recipients (20), and in renal transplant recipients (28).…”

Section: Discussionsupporting

confidence: 85%

Preventing Bone Loss in Renal Transplant Recipients with Vitamin D

El‐Agroudy

El-Husseini

El‐Sayed

et al. 2003

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Abstract. Very rapid bone loss, osteopenia, and osteoporosis have been documented in the first 6 to 12 mo after renal transplantation. Investigated was the effect of treatment with active vitamin D on the prevention of posttransplantation bone loss. Forty adult men who were recent renal transplant recipients were enrolled onto the study. Patients were randomized into two groups: group 1 received daily alfacalcidol 0.5 g by mouth, and group 2 (control) received placebo. Every patient in both groups received daily 500-mg calcium carbonate supplements. Parameters of bone metabolism and bone mineral density measured at three sites were assessed before and after the study period. Bone mineral density was increased by 2.1%, 1.8%, and 3.2% at lumbar spine, femoral neck, and forearm, respectively, in group 1, whereas it decreased by 3.2%, 3.8%, and 1.8% at the same sites in the control group (P Ͻ 0.05). Serum intact parathyroid hormone level decreased significantly in group 1 compared with the control group (P ϭ 0.003). Early bone loss that occurs during the first 1 yr after renal transplantation could be prevented by alfacalcidol. Use of alfacalcidol early after transplantation is safe and well tolerated.

show abstract

Section: Discussionsupporting

confidence: 85%

Preventing Bone Loss in Renal Transplant Recipients with Vitamin D

El‐Agroudy

El-Husseini

El‐Sayed

et al. 2003

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…After 1 year of treatment with 1-hydroxycholecalciferol (alfacalcidol) there was an improvement in BMD compared to the non-treated control group. These results are in agreement with many other studies, which could demonstrate substantial improvement of bone mass after transplantation (27)(28)(29)(30)(31). The high percentage of patients with mildly elevated PTH and alkaline phosphatase levels may be related to persistence of secondary hyperparathyroidism, which started prior to transplantation and present in some patients with mildly impaired graft function.…”

Section: Discussionsupporting

confidence: 92%

A Prospective Randomized Study for the Treatment of Bone Loss with Vitamin D During Kidney Transplantion in Children and Adolescents

El‐Husseini¹,

El‐Agroudy

El‐Sayed

et al. 2004

American Journal of Transplantation

View full text Add to dashboard Cite

The effect of treatment with alfacalcidol on posttransplantation bone loss in children and adolescents was investigated.Of the 63 young patients who received renal transplant and were subjected to dual-energy x-ray absorptiometry (DEXA), 30 patients had low-bone mineral density (BMD) (z-score ≤ −1) and were enrolled into the study. Their mean age at the time of transplantation was 14.5 ± 4.0 years and the mean duration after transplantation was 48 ± 34 months. Patients with low BMD were randomized into two equal homogeneous groups: group 1 (control) received placebo and group 2 received daily alfacalcidol 0.25 lg by mouth. Parameters of bone metabolism (intact parathyroid hormone, serum osteocalcin and urinary deoxypyridinoline) and BMD were assessed before and after the study period.After 12 months of treatment BMD at the lumber spine decreased from −2.2 to −2.5 in group 1 while it increased from −2.1 to −0.6 in group 2 (p < 0.001). Serum intact parathyroid hormone level decreased significantly in group 2 (p = 0.042). Apart from transient hypercalcemia in 1 patient in group 2, no other significant adverse effects were noted. This study suggested the value of alfacalcidol in the treatment of bone loss in young renal transplant recipients.

show abstract

“…5,65,66 Until recently, effects on fracture risk have not been well studied. Treatments proposed include bisphosphonates, hormone replacement therapy (HRT), vitamin D (cholecalciferol or calciferol) and calcium, calcitriol, calcidiol, alfacalcidol, calcitonin, fluoride, testosterone and anabolic steroids.…”

Section: Treatment and Treatment Thresholdsmentioning

confidence: 99%

“…5,25,65,67,69,70,224 Under most of these guidelines, patients taking glucocorticoids should be considered for treatment where BMD is found to be below a given threshold, such as the threshold for osteoporosis. If, as has been shown in the present report, the risk of fracture with the use of corticosteroids is not wholly dependent on BMD, then fracture risk assessment should take into account the independent risk associated with glucocorticoids and a history of prior fracture.…”

Section: Intervention Strategiesmentioning

confidence: 99%

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis

Kanis¹,

Stevenson²,

McCloskey³

et al. 2007

Health Technol Assess

135

134

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Treatment of Glucocorticoid-Induced Osteoporosis with Alfacalcidol/Calcium Versus Vitamin D/Calcium

Cited by 65 publications

References 23 publications

Preventing Bone Loss in Renal Transplant Recipients with Vitamin D

Preventing Bone Loss in Renal Transplant Recipients with Vitamin D

A Prospective Randomized Study for the Treatment of Bone Loss with Vitamin D During Kidney Transplantion in Children and Adolescents

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis

Contact Info

Product

Resources

About